Tony Durkin Mailing List

Monday, April 26, 2010

JNL: Functional Imaging Using Diffuse Optical Spectroscopy of Neoadjuvant Chemotherapy Response in Women with Locally Advanced Breast Cancer


Clin Cancer Res; 16(9); 2605–14. ©2010 AACR.
  1. Hany Soliman1,4,
  2. Anoma Gunasekara4,
  3. Mary Rycroft4,
  4. Judit Zubovits2,
  5. Rebecca Dent3,
  6. Jacqueline Spayne1,
  7. Martin J. Yaffe4,5, and
  8. Gregory J. Czarnota1,4,5
+ Author Affiliations
1.      Authors' Affiliations: Departments of 1Radiation Oncology, 2Pathology, and 3Medical Oncology, Sunnybrook Health Sciences Centre and Faculty of Medicine, University of Toronto; 4Imaging Research, Sunnybrook Health Sciences Centre; 5Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
  1. Corresponding Author:
    Gregory J. Czarnota, Department of Radiation Oncology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Room T2-167, Toronto, Ontario, Canada M4N 3M5. Phone: 416-480-6128; Fax: 416-480-6002; E-mail: Gregory.Czarnota@sunnybrook.ca.

Abstract

Purpose: Functional imaging with tomographic near-infrared diffuse optical spectroscopy (DOS) can measure tissue concentration of deoxyhemoglobin (Hb), oxyhemoglobin (HbO2), percent water (%water), and scattering power (SP). In this study, we evaluated tumor DOS parameters and described their relationship to clinical and pathologic outcome in patients undergoing neoadjuvant therapy for locally advanced breast cancer.
Experimental Design: Ten patients were enrolled and intended to undergo five scans each. Scans were taken up to 3 days before treatment and at 1, 4, and 8 weeks after neoadjuvant treatment before surgery. Changes in volume of interest weighted tissue Hb, HbO2, %water, and SP corresponding to the tumor were compared with clinical and pathologic response.
Results: All patients' tumor volumes of interest were significantly different compared with background tissue for all parameters. Five patients had a good pathologic response. Four patients were considered nonresponders. One patient initially did not respond to chemotherapy but, after a change in chemotherapy, had a good response. In the five patients with a good response, the mean drop in Hb, HbO2, %water, and SP from baseline to the 4-week scan was 67.6% (SD = 20.8), 58.9% (SD = 20.3), 51.2% (SD = 28.3), and 52.6% (SD = 26.4), respectively. In contrast, the four nonresponders had a mean drop of 17.7% (SD = 9.8), 18.0% (SD = 20.8), 15.4% (SD = 11.7), and 12.6% (SD = 10.2) for Hb, HbO2, %water, and SP, respectively.
Conclusions: Responders and nonresponders were significantly different for all functional parameters at the 4-week scan, except for %water, which approached significance. Thus, DOS could be used as an early detector of tumor response. Clin Cancer Res; 16(9); 2605–14. ©2010 AACR.